Non-steroidal anti-inflammatory drugs do not influence the urinary testosterone/epitestosterone glucuronide ratio

Frontiers in Endocrinology

Volumn 4, Issue MAY, 2013, Pages

  Lundmark, Jonas ^a   Gårevik, Nina ^a   Thörngren, John Olof ^a   Garle, Mats ^a   Ekström, Lena ^a   Rane, Anders ^a   Schulze, Jenny J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Diclofenac; Epitestosterone; Ibuprofen; NSAID; T E ratio; Testosterone; UGT2B17

Indexed keywords

DICLOFENAC; EPITESTOSTERONE; GLUCURONOSYLTRANSFERASE; IBUPROFEN; METHYLTESTOSTERONE; TESTOSTERONE ENANTATE; TRIACYLGLYCEROL;

ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; STEROID EXCRETION; URINALYSIS;

EID: 84884187538     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2013.00051     Document Type: Article

References (30)

1. Alaranta, A., Alaranta, H., and Helenius, I. (2008). Use of prescription drugs in athletes. Sports Med. 38, 449-463.
2. Belanger, A., Pelletier, G., Labrie, F., Barbier, O., and Chouinard, S. (2003). Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol. Metab. 14, 473-479.
3. Coffman, B. L., King, C. D., Rios, G. R., and Tephly, T. R. (1998). The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos. 26, 73-77.
4. Davies, N. M. (1998). Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin. Pharmacokinet. 34, 101-154.
5. de la Torre, X., Segura, J., Yang, Z., Li, Y., and Wu, M. (1997). "Testosterone detection in different ethnic groups," in Recent Advances in Doping Analysis (4), eds W. Schänzer, H. Geyer, A. Gotzman, and U. Mareck-Engelke (Köln: Sport und Buch Strauss), 71-89.
6. Donike, M., Adamietz, B., Opfermann, G., Schänzer, W., Zimmermann, J., and Mandel, F. (1985). "Die normbereiche für testosteron- und epitestosterone urinspiegel sowie des testosteron-/epitestosteron-quotienten," in Training und Sport zur Prävention und Rehabilitation in der Technisierten Umwelt, eds H. Mellerowicz, I. W. Franz, and W. Noack (Berlin: Springer Verlag), 503-507.
7. Donike, M., Bärwald, K., Klostermann, K., Schänzer, W., and Zimmermann, J. (1983). "Detection of exogenous testosterone," in Sport:Leistung und Gesundheit, Kongressbd. Dtsch Sportarztekongress, eds H. Heck, W. Hollmann, H. Liesen, and R. Rost (Köln: Deutcher ärtzte-Verlag), 293-298.
8. Garcia-Martin, E., Martinez, C., Tabares, B., Frias, J., and Agundez, J. A. (2004). Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther. 76, 119-127.
9. Guillemette, C. (2003). Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3, 136-158.
10. Handelsman, D. J., and Heather, A. (2008). Androgen abuse in sports. Asian J. Androl. 10, 403-415.
11. Jakobsson, J., Ekstrom, L., Inotsume, N., Garle, M., Lorentzon, M., Ohlsson, C., et al. (2006). Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J. Clin. Endocrinol. Metab. 91, 687-693.
12. Jenkinson, C., Petroczi, A., Barker, J., and Naughton, D. P. (2012a). Dietary green and white teas suppress UDP-glucuronosyltransferase UGT2B17 mediated testosterone glucuronidation. Steroids 77, 691-695.
13. Jenkinson, C., Petroczi, A., and Naughton, D. P. (2012b). Red wine and component flavonoids inhibit UGT2B17 in vitro. Nutr. J. 11, 67.
14. Kiang, T. K., Ensom, M. H., and Chang, T. K. (2005). UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 106, 97-132.
15. Kuehl, G. E., Lampe, J. W., Potter, J. D., and Bigler, J. (2005). Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab. Dispos. 33, 1027-1035.
16. Mackenzie, P. I., Owens, I. S., Burchell, B., Bock, K. W., Bairoch, A., Belanger, A., et al. (1997). The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7, 255-269.
17. Mano, Y., Usui, T., and Kamimura, H. (2007). Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Eur. J. Clin. Pharmacol. 63, 211-216.
18. Miners, J. O., Knights, K. M., Houston, J. B., and Mackenzie, P. I. (2006). In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem. Pharmacol. 71, 1531-1539.
19. Nakamura, A., Nakajima, M., Yamanaka, H., Fujiwara, R., and Yokoi, T. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab. Dispos. 36, 1461-1464.
20. Park, J., Park, S., Lho, D., Choo, H. P., Chung, B., Yoon, C., et al. (1990). Drug testing at the 10th Asian games and 24th Seoul Olympic games. J. Anal. Toxicol. 14, 66 -72.
21. Schulze, J. J., Lorentzon, M., Ohlsson, C., Lundmark, J., Roh, H. K., Rane, A., et al. (2008a). Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes. Pharmacogenet. Genomics 18, 477-485.
22. Schulze, J. J., Lundmark, J., Garle, M., Skilving, I., Ekstrom, L., and Rane, A. (2008b). Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J. Clin. Endocrinol. Metab. 93, 2500-2506.
23. Schulze, J. J., Thorngren, J. O., Garle, M., Ekstrom, L., and Rane, A. (2011). Androgen Sulfation in Healthy UDP-glucuronosyl transferase 2B17 enzyme-deficient men. J. Clin. Endocrinol. Metab. 96, 3440-3447.
24. Sten, T., Bichlmaier, I., Kuuranne, T., Leinonen, A., Yli-Kauhaluoma, J., and Finel, M. (2009a). UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly. Drug Metab. Dispos. 37, 417-423.
25. Sten, T., Finel, M., Ask, B., Rane, A., and Ekstrom, L. (2009b). Non-steroidal anti-inflammatory drugs interact with testosterone glucuronidation. Steroids 74, 971- 977.
26. Turgeon, D., Carrier, J. S., Levesque, E., Hum, D. W., and Belanger, A. (2001). Relative enzymatic activity, protein stability, and tissue distribution of human steroidmetabolizing UGT2B subfamily members. Endocrinology 142, 778-787.
27. Van der Logt, E. M., Roelofs, H. M., Van Lieshout, E. M., Nagengast, F. M., and Peters, W. H. (2004). Effects of dietary anticarcinogens and nonsteroidal antiinflammatory drugs on rat gastrointestinal UDP-glucuronosyltransferases. Anticancer Res. 24, 843-849.
28. WADA. (2011). Laboratory Testing Figures. Montreal: Reported by Accredited Laboratories.
29. Warden, S. J. (2009). Prophylactic misuse and recommended use of non-steroidal anti-inflammatory drugs by athletes. Br. J. Sports Med. 43, 548-549.
30. Zhou, S. F., Zhou, Z. W., and Huang, M. (2010). Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278, 165-188.